Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials

OBJECTIVE: Antibody-drug conjugates (ADCs) that target human epidermal growth factor receptor 2 (HER2) are leading a new era of targeted cancer therapy. These drugs have also been associated with several fatal adverse events, such as pneumonia, interstitial lung disease, and infection. We performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Zhiwen, Gao, Chen, Xie, Jiyi, Zhang, Cong, Li, Shijun, Gu, Ming, Shi, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563201/
https://www.ncbi.nlm.nih.gov/pubmed/37817092
http://dx.doi.org/10.1186/s12885-023-11250-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563201/
https://www.ncbi.nlm.nih.gov/pubmed/37817092
http://dx.doi.org/10.1186/s12885-023-11250-1

Ejemplares similares